1-4 of 4
Michael Leukam
Close
Sort by
Journal Articles

G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Poorva Bindal, Pavania Elavalakanar, Caitlin A. Trottier, Laura E. Dodge, Emma K. Logan, David J. Sermer, Michael Leukam, Matthew J Weinstock, Robin M. Joyce, Jessica Liegel, Jacalyn Rosenblatt, David Avigan, Carolyn D. Alonso, Jon E. Arnason
Journal: Blood
Blood (2022) 140 (Supplement 1): 5238–5240.
https://doi.org/10.1182/blood-2022-167976
Published: 2022
Journal Articles

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Kirk Cahill, Michael Leukam, Theodore G. Karrison, Jessica Robertson, Justin Kline, Sonali M. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 2420.
https://doi.org/10.1182/blood-2021-152126
Published: 2021
Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 924.
https://doi.org/10.1182/blood-2019-131562
Published: 2019
Journal Articles

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W. MacNabb, Robert Orlowski, Sonali M. Smith, Justin Kline
Journal: Blood
Blood (2019) 133 (21): 2279–2290.
https://doi.org/10.1182/blood-2018-10-879015
Published: 2019
Includes: Supplemental data